证券代码：601607 证券简称：上海医药 公告编号：临2025-045 特此公告。 上海医药集团股份有限公司 1、《关于聘任公司高级管理人员的议案》 同意聘任周亚栋女士担任公司副总裁兼财务总监，任期至第八届董事会届满 时止。同时沈波先生不再担任公司财务总监职务。 表决结果：赞成 9 票，反对 0 票，弃权 0 票 注：本议案前期已提交公司第八届董事会提名委员会第五次会议及第八届董 事会审计委员会第十一次会议审议通过，同意提交董事会审议。 上海医药集团股份有限公司 第八届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海医药集团股份有限公司（以下简称"本公司"或"上海医药"）第八届 董事会第二十一次会议（以下简称"本次会议"）于 2025 年 4 月 8 日以通讯方 式召开。本次会议应到董事九名，实到董事九名，符合《中华人民共和国公司法》 和本公司章程关于董事会召开法定人数的规定。本次会议审议并通过了以下议案： 董事会 二零二五年四月九日 1 ...

上海医药集团股份有限公司 关于高级管理人员变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海医药集团股份有限公司（以下简称"上海医药"、"公司"）于 2025 年 4 月 8 日召开的第八届董事会第二十一次会议审议通过了《关于聘任公司高级管理 人员的议案》，同意聘任周亚栋女士担任公司副总裁兼财务总监，任期至第八届 董事会届满时止。同时沈波先生不再担任公司财务总监职务。周亚栋女士简历详 见附件。 证券代码：601607 证券简称：上海医药 编号：临2025-046 特此公告。 上海医药集团股份有限公司 董事会 二零二五年四月九日 附件简历： 周亚栋女士，1972 年 1 月出生，华东师范大学国际金融专业本科毕业，香 港中文大学会计学硕士，具备丰富的专业知识、工作经验和管理能力。现任上海 实业城市开发集团有限公司执行董事。曾任上海上实集团财务有限公司党支部书 记、董事、总经理，上海实业(集团)有限公司计划财务部副总经理，上海路桥发 展有限公司总经理等职。 2 1 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-044 上海医药集团股份有限公司 上海医药集团股份有限公司 董事会 二零二五年四月八日 1 近日，国际权威品牌评估机构 Brand Finance 发布《2025 年全球医药品牌 价值榜》，上海医药集团股份有限公司（以下简称"本公司"或"公司"）再度入 选榜单，排名跃升至全球第 19 位，较 2024 年提升 1 位。这是公司自 2020 年以 来连续第六年跻身全球医药品牌价值前列。 本次入选 2025 年全球最具价值医药品牌 25 强，不会对公司近期生产经营产 生重大影响，敬请广大投资者谨慎投资，注意投资风险。 特此公告。 关于入选全球最具价值医药品牌 25 强的自愿性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 ...

Market News - The National Bureau of Statistics will release March CPI and PPI data on April 10, with February figures showing a month-on-month CPI decrease of 0.2% and a year-on-year decrease of 0.7%, while PPI decreased by 0.1% month-on-month and 2.2% year-on-year [2] - The People's Bank of China has 763.4 billion yuan in reverse repos and 150 billion yuan in treasury cash deposits maturing this week, with specific amounts maturing each day [3] - The U.S. will release March CPI data on April 10, which is expected to be a significant test for the dollar, as persistent inflation could support the dollar and raise concerns about further interest rate cuts by the Federal Reserve [4] Sector Events - The 10th China Science and Technology Finance Forum will be held in Beijing on April 7, focusing on summarizing reform achievements and innovative paths for the future of technology finance [6] - The 2025 Global 6G Technology and Industry Ecosystem Conference will take place in Nanjing from April 10 to 12, gathering global leaders in the 6G field to discuss innovation and future industry development [7] - The Ministry of Commerce has announced export controls on seven categories of medium and heavy rare earths, effective immediately, to safeguard national security and fulfill international obligations [8] - Amazon plans to launch its first batch of 27 satellites for its Project Kuiper on April 9, entering competition with SpaceX's Starlink [9] Company News - HeXin Instruments plans to acquire a 56% stake in Shanghai Liangxi Technology Co., Ltd. through a combination of share issuance and cash payment [11] - Shengnong Development intends to acquire a 54% stake in Anhui Sun Valley Food Technology Group for 1.126 billion yuan, enhancing its integrated industry chain [12] - Lier Chemical expects a net profit of 145 to 155 million yuan for Q1 2025, representing a year-on-year increase of 203.08% to 223.98% due to rising sales and prices [13] - Stone Technology reported a revenue of 11.945 billion yuan for 2024, a year-on-year increase of 38.03%, and a net profit of 1.977 billion yuan, a decrease of 3.64% [14] - Chengdi Xiangjiang announced a contract worth 4.452 billion yuan for a data center project with China Mobile, with a cooperation period of seven years plus an uncertain duration [15] Restricted Shares - This week, 24 companies in the A-share market will have a total of 1.735 billion shares released from restrictions, with a total market value of 35.015 billion yuan, an increase of 12.411 billion yuan week-on-week [17] New Stock Calendar - Two new stocks are set to be issued this week, with a total of approximately 42.6 million shares and expected fundraising of 1.161 billion yuan [21] Market Outlook - Dongfang Securities suggests the market may see a turning point post-holiday, with potential for a rebound as policy benefits are released in Q2 [24] - Founder Securities believes A-shares may perform better than global markets due to positive macro policies and recovering domestic demand [25] - Dongguan Securities anticipates a range-bound market in the short term due to global volatility and upcoming earnings reports [26] - Guojin Securities recommends a shift in investment strategy towards large-cap value stocks, focusing on "profit bottom" logic in the upcoming quarter [27]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The pharmaceutical sector shows higher certainty under the backdrop of the tariff war, with a focus on innovation and domestic substitution strategies [1][15] - The A-share pharmaceutical index has increased by 1.20% this week and 4.77% year-to-date, outperforming the CSI 300 by 2.57% and 6.64% respectively [3][9] - The report highlights the approval of significant drugs in China, such as Roche's Ocrelizumab for multiple sclerosis and Novartis' Pluvicto for prostate cancer treatment [3][4] Summary by Sections Industry Performance - The A-share pharmaceutical index has shown a weekly increase of 1.20% and a year-to-date increase of 4.77%, while the H-share biotech index has increased by 1.7% this week and 30.77% year-to-date [3][9] - Notable stock performances include Duorui Pharmaceutical (+56%), Oukang Pharmaceutical (+49%), and Weisi Medical (+31%) [3][9] Tariff Impact - The recent U.S. tariff exemptions for the pharmaceutical industry include drug formulations, active pharmaceutical ingredients, and plant extracts, indicating minimal impact on the sector [3][15] - The report notes that 90% of antiviral and antibiotic drugs consumed in the U.S. rely on imported active pharmaceutical ingredients, with a significant portion coming from India and China [15][16] Investment Strategy - Recommended investment focus areas include innovative drugs, blood products, research services, and medical devices, with a specific emphasis on domestic companies benefiting from tariff changes [10][16] - Companies to watch include Baijia Shenzhou, Kelun Pharmaceutical, and Shanghai Laisai in the innovative drug sector, and Shanghai Laisai and Boya Biological in blood products [10][16] R&D Developments - Over 200 Chinese innovative drugs are set to be showcased at the 2025 AACR conference, reflecting the growing international recognition of domestic innovations [3][18] - The report lists several key drugs and their respective companies that have received U.S. approvals, highlighting the advancements in the Chinese pharmaceutical sector [18][19]

Core Viewpoint - The China Securities Index for the medical industry has shown a slight decline over the past month, quarter, and year-to-date, indicating a stable but slightly negative trend in the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry is currently at 566.67 points [1]. - Over the past month, the index has decreased by 0.49%, while it has seen a minimal decline of 0.02% over the past three months and year-to-date [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.12%) - Aier Eye Hospital (8.91%) - United Imaging Healthcare (7.39%) - Aimeike (3.93%) - Huatai Medical (3.48%) - New Industries (3.41%) - Yuyue Medical (3.12%) - Shanghai Pharmaceuticals (3.04%) - Meinian Onehealth (2.57%) - Jiuan Medical (2.39%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (57.38%) and the Shanghai Stock Exchange (42.62%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.29% - Medical Consumables: 23.16% - Pharmaceutical Commerce: 15.33% - Medical Services: 14.26% - In Vitro Diagnostics: 12.95% [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

Macro Strategy - The March PMI data indicates three characteristics of economic recovery: the pre-positioning of work due to the Spring Festival, better recovery of manufacturing demand compared to supply, and weak consumer service consumption [1][30]. - The manufacturing PMI for March is 50.5%, showing a slight increase of 0.3 percentage points from the previous month, while the service PMI is at 50.3%, also up by 0.3 percentage points [1][30]. - The new order index for manufacturing increased by 0.7 points to 51.8%, indicating stronger demand recovery compared to supply [1][30]. Industry Insights - The report highlights the need for macro policies to be adjusted in response to potential economic pressures in the second quarter, particularly in exports and real estate [1][30]. - The construction industry PMI rose to 53.4%, reflecting seasonal recovery, but remains at a historically low level for this time of year [1][30]. - The report emphasizes the importance of monitoring the impact of tariff increases on exports and the ongoing trends in the real estate market [1][30]. Company Analysis - The report provides insights into various companies, including their performance forecasts and investment ratings, such as the significant growth in sales for Lao Pu Gold and the strategic partnerships for Jianghuai Automobile [9][15]. - Companies like Yubiquitous and Geli Pharmaceutical are noted for their innovative product developments and market potential, with investment ratings maintained at "buy" [11][12]. - Shanghai Pharmaceuticals reported a revenue of 275.25 billion yuan, reflecting a 5.75% year-on-year increase, with a net profit of 4.553 billion yuan, up 20.82% [14]. Financial Performance - The report indicates that the overall financial performance of companies is under scrutiny, with adjustments made to profit forecasts for several firms based on market conditions and operational challenges [15][19]. - Companies such as China Communications Construction Company and Orient Securities are highlighted for their revenue growth and strategic adjustments in response to market dynamics [22][23]. - The report also notes the importance of cash flow management and cost control in maintaining profitability amid fluctuating market conditions [22][24].

证券代码：601607 证券简称：上海医药 编号：临2025-042 上海医药集团股份有限公司 关于 2019 年 A 股股票期权激励计划预留股票期权第三个行 权期 2025 年第一季度自主行权结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 第三次会议，审议通过了《关于 2019 年股票期权激励计划（草案）及其摘要的 议案》（以下简称"《股票期权激励计划（草案）》"）、《关于 2019 年股票期权激 励计划实施考核管理办法的议案》 股票期权激励计划相关事宜的议案》。详见公司于 2019 年 12 月 19 日在指定信息 披露媒体发布的相关公告。 第五次会议，审议通过了《关于 2019 年股票期权激励计划首次授予相关事项的 议案》。公司董事中作为激励对象的关联董事左敏先生、李永忠先生及沈波先生 均已回避表决；公司独立董事就本激励计划授予事项发表了独立意见；公司监事 会对本激励计划授予公司股票期权事项进行了核查，同意确定 2019 年 12 月 19 日为授予日，并对激励对象名单进行了核实。详见公司 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 * 僅供識別 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於 2019 年 A 股股票期權激勵計畫預留股票期權第三 個行權期 2025 年第一季度自主行權結果公告》、《上海醫藥集團股份有限公司關於向特定對 象發行限售股上市流通的公告》、《國投證券股份有限公司關於上海醫藥集團股份有限公司向 特定對象發行限售股上市流通的核查意見》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 ...

本次股票上市流通日期为 2025 年 4 月 8 日。 证券代码：601607 证券简称：上海医药 公告编号：临 2025-043 上海医药集团股份有限公司 关于向特定对象发行限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为非公开发行股份；股票认购方式为网下，上市股数为 852,626,796 股。 本次股票上市流通总数为 852,626,796 股。 一、本次限售股上市类型 经中国证券监督管理委员会《关于核准上海医药集团股份有限公司非公开发 行股票的批复》（证监许可[2022]584号）核准，上海医药集团股份有限公司（以下 简称"公司"）合计向特定对象发行人民币普通股（A股）股票852,626,796股，发 行价为人民币16.39元/股（以下简称"本次发行"）。 本次发行新增852,626,796股份已于2022年4月8日在中国证券登记结算有限责 任公司上海分公司办理完毕股份登记手续。本次发行新增股份为有限售条件流通 股，将于限售期满后的次一交易日起上市流通，相关股 ...